Recall Issued On Ground Beef Sold At H-E-B Store Feb 15, 2009
An exercise program is essential to managing psoriatic arthritis. But what kind of exercise is best, and how much exercise is appropriate. (Click2Houston, TX)
Psoriatic Arthritis Improves with Investigational Biologic Feb 15, 2009
" Ustekinumab has been approved in Europe for psoriasis. An application for U.S. marketing in psoriasis is pending. Unlike most other monoclonal antibody drugs, which require IV infusion, ustekinumab is generally delivered subcutaneously. The agent blocks interleukins 12 and 23 by binding to the P40 protein subunit that is a component of both. Previous studies have shown that this action disrupts the inflammatory cascade that is downstream of these interleukins, which plays an important role in... (MedPage Today)
Gene Insights May Improve Psoriasis Care Feb 7, 2009
In addition, 10 percent to 30 percent of patients develop psoriatic arthritis, a painful inflammation of the joints. Psoriasis can also increase the risk of coronary artery disease. (MEDLINEplus)
TNF-Blocker Therapy for RA May Trigger Psoriasis Feb 7, 2009
"These findings present an interesting paradox," Hyrich pointed out, "as anti-TNF therapies are very effective in the treatment of severe psoriasis and psoriatic arthritis. The explanation behind these reported cases remains largely unknown.". "Further observation to understand their etiology is required," she concluded, "before any definite conclusions regarding the association between anti-TNF therapies and psoriasis can be made or guidelines for specific treatment of the condition issued.". (MEDLINEplus)
Abnormal ECG Seen in Psoriatic Arthritis Patients Feb 7, 2009
NEW YORK (Reuters Health) - The results of a new study suggest that patients with psoriatic arthritis, a form of rheumatoid arthritis accompanied by psoriasis, may have "subtle" cardiac conduction disturbances ... "In surveying the literature, scant data were found regarding cardiac arrhythmias in psoriatic arthritis patients," researchers note in the Journal of Rheumatology ... Dr. Devy Zisman from Carmel Medical Center, Haifa, Israel, and colleagues compared the electrocardiogram (ECG) scans... (MEDLINEplus)
Patients With Psoriasis At Increased Risk For Developing Other Serious Medical Conditions Mar 26, 2008
Our review found that people with more severe cases of psoriasis appear to have an increased incidence of psoriatic arthritis, cardiovascular disease, hypertension, diabetes, cancer, depression, obesity and even other immune-related conditions such as Crohn s disease, said Dr. Kimball. I advise patients at minimum to follow the nationally recognized recommendations that are appropriate for their age and gender. (Science Daily)
Psoriasis Patients at Increased Risk for Other Diseases Mar 26, 2008
Our review found that people with more severe cases of psoriasis appear to have an increased incidence of psoriatic arthritis, cardiovascular disease, hypertension, diabetes, cancer, depression, obesity and even other immune-related conditions such as Crohns disease, said Dr. Kimball. I advise patients at minimum to follow the nationally recognized recommendations that are appropriate for their age and gender. (Newsmax)
Watery Pools In Bone Marrow Key To Psoriatic Arthritic Damage Mar 7, 2008
Psoriatic arthritis affects about six percent of those suffering from the autoimmune skin condition psoriasis, and can severely damage joints and bones ... "In erosive psoriatic arthritis, mistaken immune signals tell osteoclasts to keep digging, as if they were trying to get at an infection buried inside the bone," said Edward M. Schwarz, Ph ... Twenty patients with erosive psoriatic arthritis were enrolled to receive etanercept twice weekly for 24 weeks. (Science Daily)
NHS psoriasis care 'inconsistent' Feb 19, 2008
" David Chandler, of the Psoriasis and Psoriatic Arthritis Alliance, said: "The report supports anecdotal evidence from those that contact us about the inconsistencies of treatment and facilities in the UK.. "Living with a disease that affects you 24 hours a day, 365 days a year is depressing enough, but to then find out that if you lived in a different location you would get better care is just an added burden.". (BBC News -- UK)
Psoriatic Arthritis Does Not Raise Risk of Cancer Feb 12, 2008
NEW YORK (Reuters Health) - Overall, people who suffer from psoriatic arthritis do not appear to have a higher risk of cancer compared to the general population, according to a new study ... To investigate further, they analyzed 665 patients who were followed from 1978 to 2004 at the University of Toronto Psoriatic Arthritis Clinic ... When Gladman's team compared the rates of first malignancy in their patients with rates in the general population, they found that psoriatic arthritis patients... (MEDLINEplus)
Johnson & Johnson Psoriasis Therapy Eases Symptoms With Fewer Injections Feb 3, 2008
Amgen plans to defend Enbrel's market share lead with data showing it has proven safe for five years on the market for psoriatic arthritis, a condition that combines symptoms of psoriasis and rheumatoid arthritis, Amgen spokeswoman Sonia Fiorenza said in a telephone interview. Enbrel was first approved for rheumatoid arthritis in 1998 and for psoriasis in 2004. (Bloomberg -- US)
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis Jan 19, 2008
It was approved for moderate to severe rheumatoid arthritis in 2002, psoriatic arthritis in 2005, ankylosing spondylitis in 2006, and moderate to severe Crohn's disease in 2007 ... Up to 30 percent of psoriasis patients develop psoriatic arthritis, which combines skin symptoms with arthritis symptoms, including joint pain and inflammation ... "HUMIRA has demonstrated its versatility in effectively treating multiple autoimmune diseases, and this approval expands the therapeutic resources... (PR Newswire)
Adult Drug Effective in Treating Psoriasis in Children Jan 17, 2008
Nearly one-third of those with psoriasis also have what's known as psoriatic arthritis, according to the U.S. National Institutes of Health. Mild cases of the disorder may respond to over-the-counter and prescription creams and ointments. (U.S. News & World Report)
Combining Medications Often Best Strategy to Battle Rheumatoid Arthritis Nov 20, 2007
The report, Comparative Effectiveness of Drug Therapy for Rheumatoid Arthritis and Psoriatic Arthritis in Adults, was authored by the AHRQ-funded RTI International-University of North Carolina Evidence-based Practice Center in Chapel Hill, NC. It is the newest analysis from AHRQ's Effective Health Care Program. That program represents an important federal effort to compare alternative treatments for significant health conditions and make the findings public. (PR Newswire)
Centocor seeks to extend profits with new products Nov 12, 2007
Both CNTO 148 filings will also seek approvals for the drug as a treatment for ankylosing spondylitis (a chronic inflammation of the spine) and psoriatic arthritis. Both new drug candidates, neither of which currently has a brand name, are monoclonal antibodies -- biological drugs genetically engineered to seek out and inhibit specific antigens responsible for diseases. (Philadelphia Business Journal, PA)
Golimumab significantly reduced signs and symptoms of ankylosing spondylitis Nov 8, 2007
With ongoing studies for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, golimumab is being studied as a monthly SC injection and an every twelve-week intravenous (IV) infusion (approximately 30-minutes) therapy ... With ongoing studies for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, golimumab is being studied as a monthly SC injection and an every twelve-week intravenous (IV) infusion (approximately 30-minutes)... (EurekAlert!)
Phase 3 data show golimumab improved psoriatic arthritis symptoms Nov 8, 2007
Golimumab achieved primary and major secondary endpoints in the largest phase 3 biologic trial completed to date in psoriatic arthritis ... NOVEMBER 8, 2007 Patients with active psoriatic arthritis receiving monthly subcutaneous (SC) injections of golimumab (CNTO 148) experienced significant and sustained improvements in the joint and skin manifestations of the disease, according to findings from the largest Phase 3 biologic study ever completed in subjects with psoriatic arthritis ...... (EurekAlert!)
REMICADE becomes first anti-TNF biologic therapy to treat 1 million patients worldwide Nov 7, 2007
Through a long line of firsts in the biotechnology industry, the history of REMICADE includes 15 FDA indications spanning across inflammatory diseases that include Crohns disease (adult and pediatric), ulcerative colitis, rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis and psoriasis ... In October 2004, REMICADE became the first TNF-alpha inhibitor approved for the treatment of active and progressive psoriatic arthritis in patients who have responded inadequately to... (EurekAlert! -- Business News)
National Psoriasis Foundation Marks World Psoriasis Day With Call to Support Psoriasis Legislation Oct 26, 2007
World Psoriasis Day, now in its fourth year, is a global effort to raise public awareness about psoriasis and psoriatic arthritis and the seriousness of these diseases ... 5 million people have psoriasis, the Psoriasis Foundation will ask volunteers to join our Psoriasis Action Network to draw attention to the Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 (S.1459/H.R.1188) ... "World Psoriasis Day is an excellent opportunity to educate our national leaders about... (PR Newswire)
Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients Oct 16, 2007
REMICADE has demonstrated broad clinical utility in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohns disease (PCD) and psoriasis (PsO) ... This approval establishes REMICADE as the first and only biologic therapy approved for the treatment of pediatric CD. In August 2006, REMICADE received the expanded indication for inhibiting the progression of structural damage and improving physical function... (EurekAlert!)
Mineral water resorts refocus on luxury Oct 14, 2007
The Dead Sea water also helped patients with psoriatic arthritis, which includes skin and nail problems, the group found, but some of that was attributed to the strong sunlight in the surrounding desert. Brian Hagen, program director at the UPMC Center for Sports Medicine on the South Side, said water therapy is a frequent part of the treatment for injured athletes and others at the facility. (Pittsburgh Post-Gazette, PA)
Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis Oct 4, 2007
Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohns disease and psoriasis. The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients suffering from debilitating immune disorders. (EurekAlert!)
Questions raised on gene therapy Sep 17, 2007
Who: 127 patients, all diagnosed with either rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis, which affects the spine and lower back. Where: Patients were recruited through doctors in these cities: Glendale and Tucson, Ariz. (MSNBC -- Race)
Empowerment Program Gets Patients on the PATH to Managing the Physical and Emotional Effects of Psoriatic Arthritis Sep 16, 2007
With the Help of Leading Medical and Lifestyle Experts - Plus TV Style Expert Stacy London - the National Psoriasis Foundation is Empowering Patients Through Live Seminars and Expanded Web Resources NEW YORK, Sept. 15 /PRNewswire/ -- People suffering from painful and, at times, embarrassing, psoriatic arthritis, have a new resource. Today, the National Psoriasis Foundation officially launched the 2007 PATH program -- Psoriatic Arthritis Total approach to Health -- with an interactive patient... (PR Newswire)
NICE gives green light to 3 biologics Aug 24, 2007
Meanwhile, the funding watchdog also issued its final guidance on another mAb, 's (adalimumab) for psoriatic arthritis. NICE recommended the drug's availability for patients with active and progressive psoriatic arthritis when the person has peripheral arthritis with three or more tender joints and three or more swollen joints, and the psoriatic arthritis has not responded to adequate trials of at least two standard disease-modifying anti-rheumatic drugs ... Psoriatic arthritis (psoriatic... (BiopharmaReporter.com)
Arthritis drug gets NHS approval Aug 22, 2007
----------------- ----------------- RELATED BBC SITES. Last Updated: Tuesday, 21 August 2007, 23:10 GMT 00:10 UK. (BBC News -- UK)
Three Studies Suggest Abbott's HUMIRA(R) (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis Jun 15, 2007
About HUMIRA HUMIRA is the only fully human monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS, an arthritis of the spine) and Crohn's disease in the U.S. and Europe. HUMIRA resembles antibodies normally found in the body. (PR Newswire)
Remicade data in ankylosing spondylitis show improvement in spinal mobility and spinal inflammation Jun 15, 2007
REMICADE is a monoclonal antibody that specifically targets TNF-alpha, which has been shown to play a role in Crohns disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS) psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohns disease (PCD) and psoriasis (PsO) ... This approval establishes REMICADE as the first and only biologic therapy approved for the treatment of PCD. In August 2006, REMICADE was approved for inhibiting progression of structural damage and... (EurekAlert!)
New use approved in Europe for Centocor drug Jun 8, 2007
Remicade is also approved in the European Union for rheumatoid arthritis and psoriatic arthritis. Centocor of Horsham, Pa. (Philadelphia Business Journal, PA)
Rheumatoid Illness, Smoking Can Harm Heart's Aorta May 31, 2007
Rheumatoid arthritis, psoriatic arthritis, lupus, ankylosing spondylitis, and polymyalgia were among the types of inflammatory rheumatic diseases afflicting the patients in the study. The researchers found that patients with inflammatory rheumatic disease were more likely than patients in the control group to have inflammation-related cells in their aortic tissue. (MEDLINEplus)
New insights into chronic inflammation and atherosclerosis May 25, 2007
The inflammatory rheumatic disease group included patients with rheumatoid arthritis, psoriatic arthritis, lupus, ankylosing spondylitis, polymyalgia and other diseases. Age, body mass index, family history of heart disease, and other traditional cardiovascular risk factors were similar in both groups. (EurekAlert!)
Celgene drug hits goal in mid-stage psoriasis trial May 22, 2007
Celgene said it is accelerating clinical and regulatory strategies for CC-10004 in psoriasis, psoriatic arthritis, rheumatoid arthritis and other inflammatory diseases. The company also said it was starting plans to advance CC-11050 and other compounds from this class, known as oral TNF alpha inhibitors, for chronic inflammatory diseases. (San Diego Union-Tribune -- Business)
Interleukin-12/23 Monoclonal Antibody for Psoriasis May 10, 2007
Psoriatic arthritis is an extradermal manifestation of psoriasis, and type 1 cytokines have pathologic roles in rheumatoid arthritis. In the study by Krueger et al., each of the five groups included 12 patients (19%) or 13 patients (20%) with psoriatic arthritis. (New England Journal of Medicine)
The Spondyloarthropathies May 8, 2007
Males are affected 2-3 times more often than females, except for psoriatic arthritis, which affects males and females equally. The spondyloarthropathies are also more likely to run in families than other autoimmune diseases such as systemic lupus erythematosus. (Suite101.com)
More » Apr 29, 2007
The spondyloarthropothies include alkylosing spondylitis, ulcerative colitis, psoriatic arthritis, reactive arthritis and undifferentiated spondylitis. The meeting is from 6:30-8 p.m. Monday, May 7, at St. Luke s Meridian Medical Offices, 520 S. Eagle Road, in the Lemhi Room. (Nampa Idaho Press-Tribune, ID)
Analysis of health care and actual needs of patients with psoriasis: a survey on the Italian population Apr 22, 2007
Results: The presence of psoriatic arthritis was reported in 26. 0% of patients. (BioMed Central)
Top earnings reports from the U.S. and Europe Apr 19, 2007
Some analysts estimated that the drug's revenue would be $40 million to $50 million higher after the company won approval to sell it for three new uses: a spine condition, psoriatic arthritis and Crohn's disease. "We suspect that investors will be disappointed by Humira's number in the quarter," an analyst at Bank of America, Glenn Novarro, said. (International Herald Tribune -- Business Asia)
JPMorgan records record $4.79b Apr 19, 2007
Some analysts estimated the drug's revenue would be $40 million to $50 million higher after the company won approval to sell it for three new uses: a spine condition, psoriatic arthritis, and Crohn's disease. Analysts expected Abbott to earn 52 cents a share, based on the average of 11 estimates in a Bloomberg survey. (Boston Globe)
Schering-Plough profit jumps 55% Apr 19, 2007
Remicade is a treatment for immune-mediated inflammatory disorders that Schering-Plough markets in countries outside the United States for rheumatoid arthritis, early rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease and ulcerative colitis. Among other prescription products posting higher sales in the 2007 first quarter was antibiotic Avelox, up 43 per cent to $115-million, primarily as a result of increased market share. (Globe and Mail -- Business)
Abbott Opens New Biotechnology Manufacturing Facility in Puerto Rico Apr 11, 2007
"The advanced, high-quality infrastructure of ABL can meet the exceptionally challenging and stringent processes of biologic manufacturing. With this state-of-the-art facility, we can supply HUMIRA to the growing number of patients who have come to rely on this breakthrough product." ABL is now the main production facility for HUMIRA, the only fully human monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) in the... (PR Newswire)
Video: Psoriasis Foundation Seeks Congressional Co-Sponsors for Landmark Bill Apr 5, 2007
To view the Multimedia News Release, go to: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act (PPARCCA) of 2007, also known as H.R. 1188, was introduced in the U.S. House of Representatives in February by Rep ... Some people with psoriasis also develop psoriatic arthritis, an inflammatory disease of the joints ... is a patient-driven, nonprofit organization dedicated to improving the quality of life for people with psoriasis and psoriatic arthritis. (PR Newswire)
Psoriatic Arthritis Mar 28, 2007
Inflammatory Arthritis as a Manifestation of Psoriasis. Up to 8 percent of people with psoriasis develop an accompanying arthritis with variable symptoms. (Suite101.com)
Humira Approved for Crohn's Disease Mar 1, 2007
Humira was initially approved to treat psoriatic arthritis in October 2005. It's also been sanctioned for moderate-to-severe rheumatoid arthritis, and an inflammatory disease of the spine called ankylosing spondylitis. (MEDLINEplus)
New Crohn's disease treatment Humira promises to reduce symptoms Mar 1, 2007
The drug is already used to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, a systemic rheumatic disease that affects the spine and sacroiliac joints. The deputy director of the FDA's Center for Drug Evaluation and Research, Dr. Douglas Throckmorton, says Humira has been shown in clinical trials involving 1,478 patients, to reduce the signs and symptoms of Crohn's disease. (News-Medical.net)
FDA approves new treatment for crohn's disease Feb 28, 2007
"Today's approval provides patients and their health care providers with a new treatment option. The product has been studied in 1,478 patients with Crohn's disease in four clinical trials comparing the drug to a placebo (contains no active ingredient) and two longer term extension studies. The labeling of Humira includes a boxed warning, the strongest type of label warning, that use of this product has been associated with serious, sometimes fatal, infections, including cases of tuberculosis,... (SpiritIndia)
Abbott gets FDA approval to sell arthritis drug for Crohn's disease Feb 28, 2007
Humira, Abbott's top-selling product with $2 billion in sales last year, is already approved for rheumatoid arthritis, psoriatic arthritis, and spinal arthritis. The new approval may generate $400 million to $500 million in additional sales, said an Abbott spokeswoman. (Boston Globe)
Psoriasis Foundation Consensus Statement Examines Psoriasis Severity in a New Light Feb 20, 2007
The current classification system has limitations and does not take into account other factors that can influence severity, such as location of psoriasis, type of psoriasis, diagnosis of psoriatic arthritis, and the influence of psoriasis on patient quality of life ... Ten percent to 30 percent of people with psoriasis also develop psoriatic arthritis, an inflammatory disease which causes pain, stiffness and swelling in and around the joints ... About the National Psoriasis Foundation The... (PR Newswire)
2 new treatments for Crohn's due soon Feb 19, 2007
Within days, Illinois-based expects to win federal approval to sell its drug, Humira , currently used to treat rheumatoid arthritis, psoriatic arthritis, and a disease that causes arthritis of the spine, to combat the intestinal disorder. The new use could produce up to about $500 million in annual revenue for a drug that is produced at Abbott's facility in Worcester. (Boston Globe)
First-Ever Psoriasis Legislation Introduced in Congress Feb 17, 2007
The Psoriasis and Psoriatic Arthritis Research, Care and Cure Act (PPARCCA) of 2007, is also supported by Reps ... "I believe it's important to recognize the pain caused by psoriasis and psoriatic arthritis, and we have put forward this legislation to make treatments more accessible and find a cure for those living with these diseases," said Rep ... "It is my hope that this bill will serve the needs of those afflicted and the community that supports them." The legislation specifically calls on... (PR Newswire)
Psoriasis Group Responds to 'Stunning' Results of CNTO 1275 Clinical Trial Feb 8, 2007
CNTO 1275 is produced by Centocor, which also makes Remicade, approved for the treatment of psoriasis, psoriatic arthritis and other diseases. Centocor's press release reports that the company is moving forward to Phase Three testing of CNTO 1275. (PR Newswire)
Weathering a personal storm with a smile Feb 7, 2007
What most people don t know is that Pat has been suffering from Psoriatic arthritis ... Pronounced (sore-EE-AA-tick), Psoriatic arthritis causes pain and swelling in some joints and scaly skin patches on some areas of the body. (Dublin Courier Herald, GA)
Survey indicates people with chronic moderate to severe plaque psoriasis may be undertreated Feb 3, 2007
The National Psoriasis Foundation is the leading patient-driven, nonprofit organization dedicated to improving the quality of life millions of Americans with psoriasis and/or psoriatic arthritis, and their families. The Psoriasis Foundation focuses on education, advocacy and research toward better treatments and a cure. (EurekAlert!)
The problem with treating spondylarthritis with anti-TNF strategies Jan 30, 2007
Any form of arthritis that affects one or more vertebral joints, spondylarthritis (SpA) represents a group of closely related disorders, including ankylosing spondylitis (AS), psoriatic arthritis (PsA), and arthritis associated with inflammatory bowel disease. Aside from chronic inflammation, these conditions are all characterized by ankylosis, stiffness and fusion of bone in the spine and peripheral joints, provoked by abnormal cartilage and bone formation. (EurekAlert!)
Sluggishness of psoriasis drug sales raises questions on prices Jan 24, 2007
In some cases the condition is linked to a joint disease known as psoriatic arthritis ... Humira, from Abbott Laboratories, is approved for psoriatic arthritis and is now being tested for psoriasis itself. (International Herald Tribune -- Business)
